Is MOTS-c Legal in Pennsylvania?
HealthRX.com
MOTS-c is unapproved and on no FDA bulks list
See the public record for MOTS-c
At a glance
- FDA approval / None; MOTS-c is not a component of any approved drug [1]
- FDA bulks lists / Not on the pharmacy list or the outsourcing-facility list [2][3][8]
- FDA interim categories / In the nominated-but-withdrawn table, outside all three categories [9]
- Pennsylvania oversight / Pharmacy and medicine boards assess licensees case by case against professional standards [6][7]
- Advisory committee / Voted in favor of listing on July 23, 2026; advice only [10][4]
- HHS draft policy / Names MOTS-c acetate; discretionary, not an approval [4][5]
- Human data / FDA found no published study in which MOTS-c was given to a person [1]
- Sport / Prohibited at all times by WADA, S4.4.1 [11]
The short answer for Pennsylvania
MOTS-c has no USP or NF monograph, is not a component of an FDA-approved drug, and is not on FDA's pharmacy bulks list, so it does not meet the federal conditions for compounding from bulk [1][2][8]. A separate draft HHS policy proposes limited enforcement discretion for MOTS-c acetate when specified conditions are met [4][5]. FDA's July 2026 review also found no listing in the European or Japanese pharmacopeias and no product authorized by the European Medicines Agency [1]. MOTS-c appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is absent from FDA's separate list for outsourcing facilities [2][3][8].
In Pennsylvania, the State Board of Pharmacy regulates pharmacies, pharmacists and pharmacy technicians, and its stated role is to decide case by case whether a licensee engaged in unprofessional conduct by departing from an ethical or quality standard of the profession [6]. The State Board of Medicine describes the same case-by-case role for the professionals it regulates, including physicians [7].
What federal law says about a MOTS-c prescription
A state-licensed pharmacy may compound from a bulk substance only if the substance complies with an applicable USP or NF monograph, is a component of an FDA-approved drug product, or appears on FDA's list of bulk substances that can be used in compounding [8]. MOTS-c meets none of those conditions [1][2][8].
MOTS-c also sits in the "nominated but withdrawn" table on FDA's page about bulk substances that may present significant safety risks; that table holds substances previously in category 2 whose nominators withdrew them [9]. FDA's stated concerns are that it has not identified any human exposure data for MOTS-c products by any route, that important safety information is lacking, and that injectable peptides may pose immunogenicity risk from aggregation and impurities [9]. Removal from category 2 was not a finding that the substance is safe [9]. No outsourcing facility reported compounding MOTS-c between January 2017 and December 2025 [1].
The July 2026 advisory committee vote
FDA's Pharmacy Compounding Advisory Committee took up MOTS-c free base and MOTS-c acetate on July 23, 2026; the uses FDA evaluated were obesity and osteoporosis [10]. The committee voted in favor of adding it to the bulks list, against FDA staff's recommendation [4]. That vote is advice only and not binding; MOTS-c is not on the list, and adding it requires formal rulemaking [4].
FDA staff had proposed that neither the free base nor the acetate be added. Their reasons: the substance is not well characterized (inconsistent naming, no impurity, aggregate or endotoxin data), its use in compounding is unknown, there are no animal toxicity studies, and FDA-approved treatments already exist for obesity and osteoporosis, two of the nominated uses [1]. The nominated products were 5 mg and 10 mg subcutaneous injections [1].
The October 2026 HHS draft policy, and what it does not do
HHS filed a draft enforcement-discretion policy for certain compounded peptides on October 28, 2026 (Federal Register document 2026-22192), scheduled for publication October 30, 2026, with comments due two weeks after publication [4]. It names MOTS-c among six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) and covers MOTS-c acetate given by subcutaneous or intramuscular injection [4][5].
Under the draft, HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with the peptide if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading "This is a compounded drug product. Not for resale." [4][5].
The notice says the policy "does not establish any rights for any person and is not binding on HHS or the public," and HHS may revisit it if a safety signal or product quality issue arises [4]. It is not an FDA approval and does not place MOTS-c on any list [4].
What is actually known about MOTS-c in people
FDA found no published study in which MOTS-c, compounded or not, was given to a human; the 12 papers the nominator cited were not clinical studies [1]. The peptide is sold on websites alone and in combinations, including an IV cocktail offered by a wellness clinic, for metabolism, weight loss, glucose control, performance and anti-aging [1].
The pharmacology comes from cells and rodents. In the 2015 discovery paper, Lee and colleagues described a 16-amino-acid peptide encoded in mitochondrial DNA; in mice, treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the main target and AMPK activated [12]. In a 2021 Nature Communications study, MOTS-c improved physical performance in young, middle-aged and old mice, and late-life intermittent treatment increased physical capacity and healthspan; in humans that study showed exercise raises the body's own MOTS-c in muscle and circulation, and nobody was given the peptide [13]. A separate randomized trial of 30 healthy adults found circulating humanin rose after endurance exercise while MOTS-c showed only a trend to increase, and plasma MOTS-c was not related to fitness [14].
On safety, FDA's adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports [1]. FDA found no pharmacokinetic data in humans or live animals; the only kinetic observation is rapid breakdown in human blood in vitro, which raises the question of whether injection can produce active levels [1]. There is no approved dose and no human dosing study [1]. With no animal toxicity studies either, safety in people is unknown, and the agency's stated concern for the injectable form is immunogenicity from aggregation and peptide-related impurities [1][9].
Sport: WADA prohibits it
WADA's Prohibited List names MOTS-c in S4.4.1 among activators of AMP-activated protein kinase. It is prohibited at all times, in and out of competition, and S4.4 substances are non-Specified Substances [11]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [11][15]. FDA notes it was already on the 2024 List [1].
What this means for someone in Pennsylvania
A prescription does not change the federal position. A patient-specific prescription is one condition of the draft HHS policy; it is not one of the routes that lets a pharmacy use a bulk substance under federal law [8][4]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [4]. For a Pennsylvania resident the picture is a peptide that is not approved and not on either bulks list, covered only by a draft enforcement-discretion policy, with Pennsylvania's pharmacy and medicine boards assessing licensees case by case [1][2][3][4][6][7].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Questions worth asking
Frequently asked questions
Is MOTS-c legal in Pennsylvania?
Is MOTS-c FDA-approved?
Did an FDA committee vote to approve or list MOTS-c?
Does the HHS peptide policy make MOTS-c legal?
Has MOTS-c been tested in people?
Is MOTS-c banned in sport?
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Pharmacy | Department of State | Commonwealth of Pennsylvania.
- Medicine | Department of State | Commonwealth of Pennsylvania.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- World Anti-Doping Agency.